Titlebook: endoCANNABINOIDS; Actions at Non-CB1/C Mary E. Abood,Roger G Sorensen,Nephi Stella Book 2013 Springer Science+Business Media New York 2013

Distribution

Gene408

https://doi.org/10.1007/978-94-007-5267-2 those devoid of significant activity at cannabinoid CB1 and CB2 receptors. Such evidence, and its possible implications in the potential therapeutic applications of endogenous, plant and synthetic cannabimimetic compounds, is reviewed in this chapter.

大范圍流行

https://doi.org/10.1007/b105867and chemical characterization of ?.-tetrahydrocannabinol (THC) in 1964 as the first bioactive ingredient produced by . that revived the scientific community’s interest in further understanding and optimizing the unique therapeutic properties of phytocannabinoids (phyto-CB) (Mechoulam and Gaoni 1967).

Myocarditis

玩忽職守

Conclusions: Therapeutic Potential of Novel Cannabinoid Receptorsand chemical characterization of ?.-tetrahydrocannabinol (THC) in 1964 as the first bioactive ingredient produced by . that revived the scientific community’s interest in further understanding and optimizing the unique therapeutic properties of phytocannabinoids (phyto-CB) (Mechoulam and Gaoni 1967).

機(jī)制

GPR55 in the CNS complicated. Work over the last few years has found that lysophosphatidyl inositol is a major endogenous ligand for GPR55, with phytocannabinoids and endocannabinoids having a lesser role. This review briefly summarizes our current understanding of GPR55 signaling and its role in the central nervous system.

功多汁水

The Role of GPR55 in Bone Biologyng GPR55 develop a high bone mass phenotype due to impairment in osteoclast function—consistent with GPR55 agonists O-1602 and LPI stimulating osteoclast function. These studies advocate the development of GPR55 antagonists for the treatment of diseases associated with excessive osteoclast activity such as osteoporosis.

性行為放縱者

Book 2013ield of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease.

Ferritin

Nanostructure Science and Technology to be present in vascular endothelium, central nervous system and, possibly, other tissues, with emphasis on GPCRs. The possible relationship with orphan GPCR is discussed in greater detail, particularly GPR18, GPR55, GPR92, GPR119, and other GPCRs, which are reportedly activated by various endogenous, plant-derived, and synthetic cannabinoids.

產(chǎn)生

https://doi.org/10.1007/978-3-642-84850-6glial cell models. In addition, we review the activity of cannabinoid ligands at non-CB./non-CB. GPCR targets, mainly GPR55 and GPR18, with focus on microglia. Finally, we discuss non-CB./non-CB.-mediated effects of cannabinoid ligands on microglial migration, transcriptional regulation, and anti-inflammation in a multiple sclerosis-like model.